Corticosteroids, cyclophosphamide, and chlorambucil therapy of membranous nephropathy
- PMID: 12923723
- DOI: 10.1016/s0270-9295(03)00052-4
Corticosteroids, cyclophosphamide, and chlorambucil therapy of membranous nephropathy
Abstract
Corticosteroids and cytotoxic agents have been studied widely in membranous nephropathy (MN). However, controlled studies with corticosteroids have not shown a clear benefit of these agents on the outcome of the disease. Some controlled trials reported that cytotoxic agents can reduce proteinuria significantly, but it was difficult to assess the efficacy of these drugs in protecting renal function because of the short follow-up period of the studies. Three randomized controlled trials showed that a 6-month treatment regimen based on corticosteroids and a cytotoxic agent, giving each for 1 month at a time in an alternating schedule, could favor remission of the nephrotic syndrome and protect renal function. Taken together, the results of these trials at the end of the follow-up period, 74% of the 174 treated patients were without nephrotic syndrome, 4 patients were on chronic dialysis, and 2 patients died. Good results with cytotoxic drugs, often associated with corticosteroids, also have been reported in progressive membranous nephropathy. However, in patients with renal insufficiency side effects were frequent and severe. Moreover, in most cases renal function improved but did not return to normal.
Similar articles
-
Treatment of membranous nephropathy.Nephrol Dial Transplant. 2001;16 Suppl 5:8-10. doi: 10.1093/ndt/16.suppl_5.8. Nephrol Dial Transplant. 2001. PMID: 11509678 Review.
-
A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.J Am Soc Nephrol. 1998 Mar;9(3):444-50. doi: 10.1681/ASN.V93444. J Am Soc Nephrol. 1998. PMID: 9513907 Clinical Trial.
-
Treatment of idiopathic membranous nephropathy (IMN).Ren Fail. 2000 Nov;22(6):697-709. doi: 10.1081/jdi-100101957. Ren Fail. 2000. PMID: 11104159 Review.
-
[Treatment of membranous nephropathy with chronic renal insufficiency].G Ital Nefrol. 2008 Nov-Dec;25 Suppl 44:76-82. G Ital Nefrol. 2008. PMID: 19048590 Italian.
-
[Treatment of idiopathic membranous nephropathy].G Ital Nefrol. 2004 Nov-Dec;21(6):531-9. G Ital Nefrol. 2004. PMID: 15593020 Review. Italian.
Cited by
-
Primary membranous nephropathy: an endless story.J Nephrol. 2023 Mar;36(2):563-574. doi: 10.1007/s40620-022-01461-3. Epub 2022 Oct 17. J Nephrol. 2023. PMID: 36251213 Review.
-
Membranous nephropathy: Treatment outline and risk stratification.Avicenna J Med. 2012 Jul;2(3):60-64. doi: 10.4103/2231-0770.102278. Avicenna J Med. 2012. PMID: 23826548 Free PMC article.
-
Inhibiting DNA Polymerases as a Therapeutic Intervention against Cancer.Front Mol Biosci. 2017 Nov 21;4:78. doi: 10.3389/fmolb.2017.00078. eCollection 2017. Front Mol Biosci. 2017. PMID: 29201867 Free PMC article. Review.
-
Membranous glomerulonephritis: treatment response and outcome in children.Pediatr Nephrol. 2009 Feb;24(2):301-8. doi: 10.1007/s00467-008-1005-9. Epub 2008 Oct 10. Pediatr Nephrol. 2009. PMID: 18846392
-
Membranous nephropathy in the older adult: epidemiology, diagnosis and management.Drugs Aging. 2007;24(9):717-32. doi: 10.2165/00002512-200724090-00002. Drugs Aging. 2007. PMID: 17727303 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical